|

Alintegimod Clinical Trials

1 actively recruiting trial across 1 location

Also known as: 7HP349

Pipeline

Phase 1/2: 1

Top Sponsors

  • 7 Hills Pharma, LLC1

Indications

  • Liver Disease1
  • ALK Genomic Tumor Aberrations1
  • Anaplastic Lymphoma Kinase Genomic Tumor Aberrations1
  • MSI-High1
  • Mismatch Repair Deficiency1

Lake Mary, Florida1 trial

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Florida Cancer Specialists

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.